NEW YORK — Researchers are testing groundbreaking treatments for autoimmune diseases like rheumatoid arthritis, multiple sclerosis, and lupus, aiming to reprogram patients’ immune systems rather than simply suppress them.
Current therapies control the immune system’s “friendly fire” but do not address the underlying problem. Patients often face a lifetime of costly medications with serious side effects, and many still struggle to keep their disease in check.
“We’re entering a new era,” said Dr. Maximilian Konig, a rheumatologist at Johns Hopkins University. These approaches “offer the chance to control disease in a way we’ve never seen before.”
One promising therapy, CAR-T, originally developed for hard-to-treat blood cancers, modifies a patient’s T cells to destroy malfunctioning B cells responsible for autoimmune attacks. Early studies in Germany and the U.S. have shown dramatic results, including drug-free remission in some patients.
Mileydy Gonzalez, 35, from New York, experienced severe lupus symptoms that affected her lungs and kidneys. After joining an experimental CAR-T study at NYU Langone Health, she gradually regained strength and energy. “I can actually run, I can chase my kid,” she said. “I had forgotten what it was to be me.”
Other approaches include engineering regulatory “peacekeeper” T cells, using lab-made antibodies called T cell engagers, and delivering instructions via mRNA to help the immune system restore balance. These therapies aim to precisely target rogue immune cells while preserving healthy ones, potentially offering long-term control or even remission.
Early successes, such as those reported by Dr. Georg Schett at the University of Erlangen-Nuremberg, have inspired a surge of clinical trials worldwide. While safety and long-term effects remain under study, patients like Allie Rubin, 60, who struggled with lupus for decades, report life-changing improvements after CAR-T treatment.
“The next 10 years will dramatically change our field forever,” Konig said, highlighting the potential of these innovative therapies to transform the treatment of autoimmune diseases.
Paraluman P. Funtanilla
Paraluman P. Funtanilla is Tutubi News Magazine's Marketing Specialist and is a Contributing Editor. She finished her degree in Communication Arts in De La Salle Lipa. She has worked as a Digital Marketer for start-up businesses and small business spaces for the past two years. She has earned certificates from Coursera on Brand Management: Aligning Business Brand and Behavior and Viral Marketing and How to Craft Contagious Content. She also worked with Asia Express Romania TV Show.
- Paraluman P. Funtanilla
- Paraluman P. Funtanilla
- Paraluman P. Funtanilla
- Paraluman P. Funtanilla
